Pliant Therapeutics: Funding, Investors & Team (Sep 2026)
Malleable Therapeutics is a clinical stage biopharmaceutical organization zeroed in on finding and creating novel treatments for the treatment of fibrosis. Flexible's lead item competitor, PLN-74809, is an oral little atom double particular inhibitor of avß6 and avß1 integrins that it is producing for the treatment of idiopathic aspiratory fibrosis, or IPF, and essential sclerosing cholangitis, or PSC. PLN-74809 has gotten Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Flexible is as of now selecting two Phase 2a preliminaries of PLN-74809 for the treatment of IPF and plans to start a Phase 2a preliminary in PSC in the last part of 2020. Flexible's second item up-and-comer, PLN-1474, is a little particle specific inhibitor of avß1 for the treatment of liver fibrosis related with nonalcoholic steatohepatitis, or NASH, which Pliant has banded together with Novartis. PLN-1474 is right now going through a Phase 1 preliminary. Notwithstanding clinical stage programs, Pliant right now has two preclinical projects focusing on oncology and solid dystrophies.
Pliant Therapeutics has raised $450M across 2 funding rounds on record, the most recent an undisclosed round of $250M announced in Jan 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Pliant Therapeutics Company Profile and Key Stats
Latest funding round on record: Jan 2023.
Pliant Therapeutics Funding Rounds
Pliant Therapeutics raised $200M in a Post-IPO Equity announced in Jul 2022.
6 months later, an undisclosed round of $250M was announced in Jan 2023.
Pliant Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Pliant Therapeutics Funding Compared to Other Biotechnology Startups
Pliant Therapeutics' latest round of $250M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Pliant Therapeutics in Biotechnology and South San Francisco
Companies Similar to Pliant Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Pliant Therapeutics Funding FAQs
What does Pliant Therapeutics do?
Malleable Therapeutics is a clinical stage biopharmaceutical organization zeroed in on finding and creating novel treatments for the treatment of fibrosis. Flexible's lead item competitor, PLN-74809, is an oral little atom double particular inhibitor of avß6 and avß1 integrins that it is producing for the treatment of idiopathic aspiratory fibrosis, or IPF, and essential sclerosing cholangitis, or PSC. PLN-74809 has gotten Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Flexible is as of now selecting two Phase 2a preliminaries of PLN-74809 for the treatment of IPF and plans to start a Phase 2a preliminary in PSC in the last part of 2020. Flexible's second item up-and-comer, PLN-1474, is a little particle specific inhibitor of avß1 for the treatment of liver fibrosis related with nonalcoholic steatohepatitis, or NASH, which Pliant has banded together with Novartis. PLN-1474 is right now going through a Phase 1 preliminary. Notwithstanding clinical stage programs, Pliant right now has two preclinical projects focusing on oncology and solid dystrophies.
How much funding has Pliant Therapeutics raised?
Pliant Therapeutics has raised $450M across 2 rounds on record. The most recent is an undisclosed round of $250M announced in Jan 2023.
When did Pliant Therapeutics last raise funding?
Pliant Therapeutics' most recent funding round on record is an undisclosed round of $250M, announced in Jan 2023.
Who founded Pliant Therapeutics?
FundedIQ lists Bill Degrado (Founder), Hal Chapman (Founder) at Pliant Therapeutics.
Where is Pliant Therapeutics headquartered?
Pliant Therapeutics is based in South San Francisco, California, United States.
How many employees does Pliant Therapeutics have?
Pliant Therapeutics is in the 101-250 employee band.
How does Pliant Therapeutics' funding compare to other Biotechnology startups?
Pliant Therapeutics' latest round of $250M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Pliant Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Pliant Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.